Analysts Set Boston Scientific Co. (BSX) PT at $31.36

Boston Scientific Co. (NYSE:BSX) has received a consensus recommendation of “Buy” from the twenty-four brokerages that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, six have given a hold recommendation, fifteen have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $31.53.

Several analysts have issued reports on the stock. Zacks Investment Research raised shares of Boston Scientific from a “sell” rating to a “hold” rating in a research note on Tuesday, January 30th. Bank of America raised their price objective on shares of Boston Scientific from $30.00 to $34.00 and gave the stock a “buy” rating in a research note on Thursday. Barclays reissued a “buy” rating and issued a $32.00 price objective on shares of Boston Scientific in a research note on Wednesday, January 10th. Morgan Stanley raised their price objective on shares of Boston Scientific from $30.00 to $33.00 and gave the stock an “overweight” rating in a research note on Monday, March 19th. Finally, TheStreet raised shares of Boston Scientific from a “c+” rating to a “b” rating in a research note on Thursday, January 18th.

How to Become a New Pot Stock Millionaire

Shares of NYSE:BSX opened at $27.35 on Wednesday. The company has a quick ratio of 0.49, a current ratio of 0.68 and a debt-to-equity ratio of 0.54. Boston Scientific has a 12 month low of $24.31 and a 12 month high of $29.93. The stock has a market capitalization of $38,621.25, a P/E ratio of 21.71, a price-to-earnings-growth ratio of 2.03 and a beta of 0.81.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.34 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.34. The business had revenue of $2.41 billion during the quarter, compared to the consensus estimate of $2.39 billion. Boston Scientific had a net margin of 1.15% and a return on equity of 24.27%. The firm’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same quarter last year, the firm earned $0.30 earnings per share. sell-side analysts forecast that Boston Scientific will post 1.37 earnings per share for the current year.

In other news, SVP John Bradley Sorenson sold 1,950 shares of Boston Scientific stock in a transaction that occurred on Monday, March 5th. The shares were sold at an average price of $27.43, for a total transaction of $53,488.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Maulik Nanavaty sold 15,568 shares of Boston Scientific stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $25.38, for a total transaction of $395,115.84. The disclosure for this sale can be found here. Insiders have sold 252,818 shares of company stock valued at $6,879,888 in the last ninety days. Insiders own 0.74% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. Bollard Group LLC increased its holdings in Boston Scientific by 0.3% during the fourth quarter. Bollard Group LLC now owns 33,854,117 shares of the medical equipment provider’s stock valued at $839,244,000 after buying an additional 118,050 shares during the period. Geode Capital Management LLC increased its holdings in Boston Scientific by 2.9% during the fourth quarter. Geode Capital Management LLC now owns 13,040,987 shares of the medical equipment provider’s stock valued at $322,533,000 after buying an additional 373,607 shares during the period. Wells Fargo & Company MN increased its holdings in Boston Scientific by 29.3% during the fourth quarter. Wells Fargo & Company MN now owns 11,945,671 shares of the medical equipment provider’s stock valued at $296,133,000 after buying an additional 2,705,194 shares during the period. OppenheimerFunds Inc. increased its holdings in Boston Scientific by 11.5% during the fourth quarter. OppenheimerFunds Inc. now owns 7,976,540 shares of the medical equipment provider’s stock valued at $197,739,000 after buying an additional 824,195 shares during the period. Finally, Boston Partners increased its holdings in Boston Scientific by 3.8% during the fourth quarter. Boston Partners now owns 7,475,797 shares of the medical equipment provider’s stock valued at $185,325,000 after buying an additional 276,390 shares during the period. 91.04% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Analysts Set Boston Scientific Co. (BSX) PT at $31.36” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://www.tickerreport.com/banking-finance/3338309/analysts-set-boston-scientific-co-bsx-pt-at-31-36.html.

About Boston Scientific

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Analyst Recommendations for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

CDW  Given Average Rating of “Buy” by Analysts
CDW Given Average Rating of “Buy” by Analysts
$0.80 Earnings Per Share Expected for Canadian National Railway  This Quarter
$0.80 Earnings Per Share Expected for Canadian National Railway This Quarter
Somewhat Favorable News Coverage Somewhat Unlikely to Affect DTS  Stock Price
Somewhat Favorable News Coverage Somewhat Unlikely to Affect DTS Stock Price
Financial Review: Torchmark  and Its Competitors
Financial Review: Torchmark and Its Competitors
TSO3  Sets New 52-Week Low at $0.90
TSO3 Sets New 52-Week Low at $0.90
Net 1 UEPS Technologies  Sets New 12-Month High and Low at $8.62
Net 1 UEPS Technologies Sets New 12-Month High and Low at $8.62


Leave a Reply

© 2006-2018 Ticker Report. Google+.